CN1244215B - 改进的腺病毒载体生产和纯化方法 - Google Patents
改进的腺病毒载体生产和纯化方法 Download PDFInfo
- Publication number
- CN1244215B CN1244215B CN971812543A CN97181254A CN1244215B CN 1244215 B CN1244215 B CN 1244215B CN 971812543 A CN971812543 A CN 971812543A CN 97181254 A CN97181254 A CN 97181254A CN 1244215 B CN1244215 B CN 1244215B
- Authority
- CN
- China
- Prior art keywords
- cell
- adenovirus
- virus
- viral
- purifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Cleaning And De-Greasing Of Metallic Materials By Chemical Methods (AREA)
- Multi-Process Working Machines And Systems (AREA)
Abstract
Description
方法 | 工艺 | 评价 |
冻融法 | 在干冰和37℃温水浴之 间循环进行 | 在实验室规模易于实施。细胞裂解效率高 不能放大 不建议用于大规模生产 |
固体剪切 | French挤压 Hughes挤压 | 需投资设备资本 有病毒污染问题 缺乏经验 |
洗涤剂裂解 | 非离子型洗涤剂溶液如吐 温、Triton、NP-40等 | 在实验室和生产规模上均易于实施 有多种洗涤剂可选 在成品中有残余洗涤剂的问题 |
低渗溶液裂 解 | 水、柠檬酸缓冲液 | 裂解效率低 |
液体剪切 | 匀浆器 冲击流 微流体化器 | 需投资设备资本 有病毒污染问题 有可放大性问题 |
超声破碎 | 超声 | 需投资设备资本 有病毒污染问题 噪音污染 有可放大性问题 |
启动子 |
免疫球蛋白重链 |
免疫球蛋白轻链 |
T-细胞受体 |
HLA DQα和DQβ |
β-干扰素 |
白细胞介素-2 |
白细胞介素-2受体 |
MHC II类5 |
MHC II类HLA-DRα |
β-肌动蛋白 |
肌酸激酶 |
前白蛋白(运甲状腺素蛋白) |
弹性蛋白酶I |
金属硫蛋白 |
胶原酶 |
白蛋白基因 |
α-胎儿蛋白 |
τ-珠蛋白 |
β-珠蛋白 |
c-fos |
C-HA-ras |
胰岛素 |
中性细胞粘着分子(NCAM) |
α<sub>1-抗胰蛋白酶</sub> |
H2B(TH2B)组蛋白 |
小鼠或I形胶原 |
葡萄糖-调节的蛋白(GRP94和GRP78) |
MHC II类HLA-DRα |
大鼠生长激素 |
人血清淀粉状蛋白A(SAA) |
肌钙蛋白I(TN I) |
血小板衍生生长因子 |
杜兴氏肌营养不良 |
SV40 |
多瘤 |
逆转录病毒 |
乳头状瘤病毒 |
乙型肝炎病毒 |
人免疫缺陷型病毒 |
巨细胞病毒 |
Gibbon猿白血病病毒 |
元件 | 诱导物 |
MT II | 佛波酯(TPA) 重金属 |
MMTV(小鼠乳腺肿瘤因子) | 促糖皮质激素 |
β-干扰素 | 聚(rI)X 聚(rc) |
腺病毒5E2 | Ela |
c-jun | 佛波酯(TPA),H<sub>2</sub>O<sub>2</sub> |
胶原酶 | 佛波酯(TPA) |
溶基质素 | 佛波酯(TPA),IL-1 |
SV40 | 佛波酯(TPA) |
小鼠MX基因 | 干扰素,新城疫病病毒 |
GRP78基因 | A23187 |
α-2-巨球蛋白 | IL-6 |
波形蛋白 | 血清 |
MHC I类基因H-2kB | 干扰素 |
HSP70 | Ela,SV40大T抗原 |
增殖蛋白 | 佛波酯-TPA |
肿瘤坏死因子 | FMA |
促甲状腺素α基因 | 甲状腺素 |
葡萄糖浓度(g/L) | 大于等于2.0 | 大于等于1.0 |
粗制病毒产量(PFU) | 4×10<sup>12</sup> | 4.9×10<sup>12</sup> |
Claims (23)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3132996P | 1996-11-20 | 1996-11-20 | |
US60/031,329 | 1996-11-20 | ||
PCT/US1997/021504 WO1998022588A2 (en) | 1996-11-20 | 1997-11-20 | An improved method for the production and purification of adenoviral vectors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1244215A CN1244215A (zh) | 2000-02-09 |
CN1244215B true CN1244215B (zh) | 2010-11-03 |
Family
ID=21858843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN971812543A Expired - Lifetime CN1244215B (zh) | 1996-11-20 | 1997-11-20 | 改进的腺病毒载体生产和纯化方法 |
Country Status (15)
Country | Link |
---|---|
US (7) | US6194191B1 (zh) |
EP (3) | EP1707631A3 (zh) |
JP (1) | JP4492826B2 (zh) |
KR (1) | KR100503701B1 (zh) |
CN (1) | CN1244215B (zh) |
AT (2) | ATE348155T1 (zh) |
AU (1) | AU732703B2 (zh) |
BR (1) | BR9713368A (zh) |
CA (1) | CA2272820C (zh) |
DE (1) | DE69737107T2 (zh) |
ES (2) | ES2278399T3 (zh) |
HK (1) | HK1107116A1 (zh) |
NO (1) | NO992389L (zh) |
NZ (1) | NZ335947A (zh) |
WO (1) | WO1998022588A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108085301A (zh) * | 2016-11-22 | 2018-05-29 | 贺道耀 | 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒 |
Families Citing this family (253)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2625279A1 (en) * | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
US20020088014A1 (en) * | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
AU3447097A (en) | 1996-07-01 | 1998-01-21 | Rhone-Poulenc Rorer S.A. | Method for producing recombinant adenovirus |
CN1244215B (zh) * | 1996-11-20 | 2010-11-03 | 荷兰克鲁塞尔公司 | 改进的腺病毒载体生产和纯化方法 |
US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
US6544769B1 (en) | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
US6995006B2 (en) * | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
WO1999021977A1 (en) * | 1997-10-24 | 1999-05-06 | Life Technologies, Inc. | Recombinational cloning using nucleic acids having recombination sites |
US7705602B2 (en) * | 1997-11-03 | 2010-04-27 | Midtronics, Inc. | Automotive vehicle electrical system diagnostic device |
US20040204381A1 (en) * | 1997-11-12 | 2004-10-14 | Moskal Joseph R | Detection and treatment of glyco-enzyme-related disease |
US6899870B1 (en) * | 1998-03-11 | 2005-05-31 | Board Of Regents, The University Of Texas System | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
SK15682000A3 (sk) * | 1998-04-22 | 2001-05-10 | Genvec, Inc. | Účinné čistenie adenovírusu |
WO2000022152A1 (en) * | 1998-10-13 | 2000-04-20 | Avigen, Inc. | Compositions and methods for producing recombinant adeno-associated virus |
US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
DE69940354D1 (de) * | 1998-11-16 | 2009-03-12 | Introgen Therapeutics Inc | Adenovirus-formulierungen zur gentherapie |
US7148035B1 (en) * | 1998-11-18 | 2006-12-12 | Oxford Biomedica (Uk) Limited | Polypeptide |
US6210922B1 (en) * | 1998-11-30 | 2001-04-03 | National Research Council Of Canada | Serum free production of recombinant proteins and adenoviral vectors |
JP2003523169A (ja) | 1998-12-31 | 2003-08-05 | アバンテイス・フアルマ・エス・アー | ウイルス粒子の分離法 |
FR2788064B1 (fr) * | 1998-12-31 | 2003-01-31 | Aventis Pharma Sa | Methode de separation de particules virales |
CA2364934C (fr) | 1999-02-22 | 2011-10-18 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
US6795585B1 (en) | 1999-07-16 | 2004-09-21 | Eastman Kodak Company | Representing digital images in a plurality of image processing states |
JP2003518380A (ja) * | 1999-12-29 | 2003-06-10 | ジェンザイム・コーポレイション | 核酸および他の細胞性汚染混入物質からウイルスベクターを分離するための濾過助剤の使用方法 |
US6168941B1 (en) * | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
AU2001257420A1 (en) * | 2000-04-28 | 2001-11-12 | Zengen, Inc. | A gene therapy system and method using alpha-MSH and its derivatives |
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
US20020064860A1 (en) * | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
BR0207527A (pt) * | 2001-03-16 | 2004-02-25 | Oncolytics Biotech Inc | Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso |
US20040146590A1 (en) * | 2001-03-22 | 2004-07-29 | Iadarola Michael J | Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin |
JP4499990B2 (ja) * | 2001-03-27 | 2010-07-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | Hcv感染に有用な組成物および方法 |
WO2003014367A1 (en) | 2001-08-08 | 2003-02-20 | The Trustees Of The University Of Pennsylvania | Method for purification of viral vectors having proteins which bind sialic acid |
AU2002332736A1 (en) * | 2001-08-30 | 2003-03-18 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | New adenovirus type 7 vectors |
ATE437222T1 (de) * | 2001-09-06 | 2009-08-15 | Alphavax Inc | Alphavirus replikon-vektorsysteme |
WO2003039459A2 (en) * | 2001-11-05 | 2003-05-15 | Genvec, Inc. | Viral vector production methods and compositions |
HU227507B1 (hu) * | 2001-12-20 | 2011-07-28 | Bavarian Nordic As | Eljárás poxvírusok kinyerésére és tisztítására fertõzött sejtekbõl |
KR100451308B1 (ko) * | 2001-12-28 | 2004-10-06 | 선바이오(주) | 단백질 의약품 정제 방법에서의 바이러스 제거 방법 |
AU2003213060A1 (en) * | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Optimization of gene sequences of chimeric virus-like particles for expression in insect cells |
ATE324467T1 (de) * | 2002-02-20 | 2006-05-15 | Merck & Co Inc | Verfahren zur konzentrationsbestimmung von adenoviruspartikeln |
US20030175688A1 (en) * | 2002-03-15 | 2003-09-18 | Rukmini Pennathur-Das | Method for the purification and production of oncolytic adenoviruses |
US20030186832A1 (en) * | 2002-03-15 | 2003-10-02 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Isotropic liquid detergents with improved anti-redeposition |
US20030180936A1 (en) * | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
CA2478932A1 (en) * | 2002-03-29 | 2003-10-16 | Merck & Co., Inc. | Large scale methods of producing adenovirus and adenovirus seed stocks |
CA2482512C (en) * | 2002-04-30 | 2011-09-20 | Oncolytics Biotech Inc. | Improved viral purification methods |
EP1506287B1 (en) * | 2002-05-14 | 2007-04-25 | Merck & Co., Inc. | Methods of adenovirus purification |
US20030224354A1 (en) * | 2002-05-30 | 2003-12-04 | Introgen Therapeutics Inc. | Quantifying viral particles with intrinsic fluorescence |
EP1371723A1 (en) * | 2002-06-12 | 2003-12-17 | Procorde GmbH | Process for preparing an adenovirus-containing preparation |
EP1543128A4 (en) * | 2002-07-18 | 2008-02-20 | Invitrogen Corp | VIRUS VECTORS WITH RECOMBINATION SITES |
AU2003268210A1 (en) * | 2002-08-28 | 2004-03-19 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
JP4560483B2 (ja) * | 2002-10-03 | 2010-10-13 | ターゲジェン インコーポレーティッド | 血管静態化物質およびそれらの使用法 |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US7319021B2 (en) * | 2002-11-01 | 2008-01-15 | Promega Corporation | Cell lysis composition, methods of use, apparatus and kit |
WO2004055167A2 (en) * | 2002-12-13 | 2004-07-01 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
ES2618309T3 (es) * | 2002-12-13 | 2017-06-21 | Alphavax, Inc. | Partículas de replicón de alfavirus multi-antigénico y métodos |
JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
CA2513251C (en) | 2003-01-14 | 2013-03-19 | Dana-Farber Cancer Institute | Cancer therapy sensitizer |
KR101518309B1 (ko) * | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
DK1620549T3 (da) * | 2003-05-01 | 2007-11-05 | Dsm Ip Assets Bv | Fremgangsmåde til fremstilling af biologiske stoffer ved perfusionsdyrkning af suspenderede dyreceller |
US20040229335A1 (en) * | 2003-05-15 | 2004-11-18 | Introgen Therapeutics, Inc. | Methods and compositions for the production of adenoviral vectors |
AU2004249199B2 (en) * | 2003-06-18 | 2008-07-24 | Onyx Pharmaceuticals, Inc. | Method for purifying virus |
DE602004021260D1 (de) * | 2003-07-11 | 2009-07-09 | Alphavax Inc | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren |
EP1648931B1 (en) | 2003-07-21 | 2011-02-09 | Transgene S.A. | Multifunctional cytokines |
EP2287341B1 (en) | 2003-12-01 | 2013-02-13 | Life Technologies Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
CA2551026A1 (en) * | 2003-12-23 | 2005-07-14 | Schering Corporation | Methods for producing a549 cell lines stable in serum-free medium suspension culture |
ES2329607T3 (es) * | 2004-02-23 | 2009-11-27 | Crucell Holland B.V. | Metodos de purificacion de virus. |
CN100333797C (zh) * | 2005-01-26 | 2007-08-29 | 彭朝晖 | 重组腺病毒p53制品在肿瘤治疗中的新用途 |
AU2005231507B2 (en) * | 2004-04-08 | 2012-03-01 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
MXPA06013124A (es) * | 2004-05-18 | 2007-05-23 | Alphavax Inc | Vectores de alfavirus derivados de tc-83, particulas y metodos. |
US7704721B2 (en) * | 2004-06-01 | 2010-04-27 | Genzyme Corporation | Compositions and methods to prevent AAV vector aggregation |
US20050287616A1 (en) * | 2004-06-29 | 2005-12-29 | Gross Adam F | Method of assaying denaturation of proteins |
JP5275628B2 (ja) | 2004-08-25 | 2013-08-28 | ターゲジェン インコーポレーティッド | 複素環式化合物および使用方法 |
DE202004014949U1 (de) * | 2004-09-25 | 2004-11-18 | Techno-Grafica Gmbh | Vorrichtung zum Wärmebehandeln einer Beschichtung von Flachoffset-Druckplatten |
DE102004049290A1 (de) * | 2004-10-09 | 2006-04-20 | Bayer Healthcare Ag | Verfahren zur Herstellung von Virusmaterial |
US7901921B2 (en) * | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
AU2005305347A1 (en) * | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | Method of producing and purifying of adenoviral vectors |
CN100497640C (zh) * | 2004-11-26 | 2009-06-10 | 中国人民解放军军事医学科学院生物工程研究所 | 一种高效生产重组腺病毒载体的方法 |
US20060166364A1 (en) * | 2004-12-22 | 2006-07-27 | Introgen, Inc. | Use of flexible bag containers for viral production |
WO2006071563A2 (en) * | 2004-12-23 | 2006-07-06 | Medimmune Vaccines, Inc. | Non-tumorigenic mdck cell line for propagating viruses |
US20060205080A1 (en) * | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
SG10201912554TA (en) | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
CA2602944C (en) * | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
CN101184780B (zh) * | 2005-05-05 | 2012-10-03 | 森馨香料公司 | β-葡聚糖和甘露聚糖的制备 |
NZ563984A (en) * | 2005-06-08 | 2011-11-25 | Targegen Inc | Methods and compositions for the treatment of ocular disorders |
WO2007005885A2 (en) * | 2005-07-05 | 2007-01-11 | David Nance | Energy recovery within a fluid distribution network using geographical information |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
DK1951684T3 (en) | 2005-11-01 | 2016-10-24 | Targegen Inc | BIARYLMETAPYRIMIDIN kinase inhibitors |
CA2646391A1 (en) * | 2006-03-22 | 2007-09-27 | Viral Logic Systems Technology Corp. | Methods for identifying polypeptide targets and uses thereof for treating immunological diseases |
US7691858B2 (en) * | 2006-04-25 | 2010-04-06 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
KR20140075022A (ko) * | 2006-09-15 | 2014-06-18 | 메디뮨 엘엘씨 | 높은 역가로 바이러스 증식을 지원하는 mdck 세포주 및 이를 이용한 생물반응기 공정 |
DK2118292T3 (da) | 2007-01-30 | 2011-10-24 | Transgene Sa | Papillomavirus E2-polypeptid der anvendes til vaccination |
US20080299624A1 (en) * | 2007-06-01 | 2008-12-04 | Edward Heslop | Continuous fermentation apparatus and method |
CA2689588C (en) | 2007-06-21 | 2016-08-23 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
JP2010539993A (ja) * | 2007-10-08 | 2010-12-24 | イントレキソン コーポレーション | 遺伝子操作した樹状細胞および癌の治療のための使用 |
PL2612868T3 (pl) | 2007-11-01 | 2018-12-31 | Astellas Pharma Inc. | Immunosupresyjne polipeptydy i kwasy nukleinowe |
US20090253184A1 (en) * | 2008-01-23 | 2009-10-08 | Introgen Therapeutics, Inc. | Compositions and methods related to an adenoviral trans-complementing cell line |
EP2806037B1 (en) * | 2008-05-13 | 2016-09-21 | Gen-Probe Incorporated | Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences |
ES2762864T3 (es) * | 2008-06-18 | 2020-05-26 | Oxford Biomedica Ltd | Purificación de virus |
CN102216450B (zh) * | 2008-09-24 | 2014-05-14 | 米迪缪尼有限公司 | 培养细胞、增殖和纯化病毒的方法 |
KR20110074563A (ko) * | 2008-09-24 | 2011-06-30 | 메디뮨 엘엘씨 | 바이러스의 정제 방법 |
WO2010060719A1 (en) | 2008-11-03 | 2010-06-03 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
WO2010062757A1 (en) * | 2008-11-03 | 2010-06-03 | Ligocyte Pharmaceuticals, Inc. | Improved methods for isolating enveloped virus-based vlps free of infectious agents |
US9523344B2 (en) * | 2009-05-26 | 2016-12-20 | Leviathan Energy Hydroelectric Ltd. | Hydroelectric in-pipe turbine uses |
US8891084B2 (en) * | 2009-07-07 | 2014-11-18 | Sony Corporation | Microfluidic device |
EP2461826A2 (en) | 2009-08-07 | 2012-06-13 | Transgene SA | Composition for treating hbv infection |
JP5393896B2 (ja) | 2009-10-15 | 2014-01-22 | クルセル ホランド ベー ヴェー | アデノウイルス粒子の精製方法 |
US8470585B2 (en) | 2009-10-15 | 2013-06-25 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
JP6151515B2 (ja) | 2010-01-05 | 2017-06-21 | バスキュラー バイオジェニックス リミテッド | 神経膠芽腫gbmを治療するための組成物および方法 |
EP3159405B8 (en) | 2010-01-05 | 2018-11-07 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
SG182490A1 (en) * | 2010-01-12 | 2012-08-30 | Vascular Biogenics Ltd | Methods of producing adenovirus vectors and viral preparations generated thereby |
PL2536829T3 (pl) | 2010-02-15 | 2016-09-30 | Sposób wytwarzania wektorów adenowirusowych Ad26 | |
BR112012026095A2 (pt) | 2010-04-14 | 2015-09-15 | Emd Millipore Corp | métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. |
CN103052399B (zh) | 2010-08-12 | 2016-06-29 | 依生生物制药控股有限公司 | 用于减少病毒组合物中dna杂质的方法 |
CN103118702A (zh) | 2010-09-20 | 2013-05-22 | 克鲁塞尔荷兰公司 | 活动性结核病的治疗性接种 |
MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
EP2461162A1 (en) | 2010-12-03 | 2012-06-06 | Texcell, . | Method for determining the titre of viruses by using infectious standards |
BR112013014457A8 (pt) | 2010-12-09 | 2017-12-19 | Pasteur Institut | usos da enzima 6-metilguanina-dna-metiltrasferase (mgmt, ec 2.1.1.63) para aumentar a produção de proteína heteróloga, bem como vetor de expressão, células recombinantes e polipeptídeo de fusão compreendendo sinal de secreção peptídica e proteína snap |
TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
WO2013045658A1 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
WO2013045668A2 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
WO2013135615A1 (en) | 2012-03-12 | 2013-09-19 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
MY169331A (en) | 2012-03-22 | 2019-03-21 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
CA2878898C (en) * | 2012-07-26 | 2023-01-17 | Vectalys | Method for detecting or measuring the impact of a viral vector composition on eukaryotic cells and biomarkers used thereof |
US9657076B2 (en) | 2012-10-23 | 2017-05-23 | Emory University | GM-CSF and IL-4 conjugates, compositions, and methods related thereto |
KR102236497B1 (ko) | 2013-04-25 | 2021-04-06 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 rsv f 폴리펩타이드 |
EP2992553A4 (en) | 2013-05-03 | 2017-03-08 | Honeywell International Inc. | Lead frame construct for lead-free solder connections |
US10294279B2 (en) | 2013-06-17 | 2019-05-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
US9956166B2 (en) | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
WO2015062699A1 (en) * | 2013-10-30 | 2015-05-07 | Merck Patent Gmbh | Method for isolating microorganisms from a complex sample |
JP2017509489A (ja) | 2014-02-20 | 2017-04-06 | ハネウェル・インターナショナル・インコーポレーテッド | 鉛フリーはんだ組成物 |
JP6783143B2 (ja) | 2014-03-25 | 2020-11-11 | テルモ ビーシーティー、インコーポレーテッド | 培地の受動的補充 |
SG11201608725YA (en) | 2014-04-25 | 2016-11-29 | Shire Human Genetic Therapies | Methods for purification of messenger rna |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
CN105316296A (zh) * | 2014-06-13 | 2016-02-10 | 亚宝药业太原制药有限公司 | 一种纯化腺病毒颗粒的方法 |
CN107074969A (zh) | 2014-09-09 | 2017-08-18 | 优努姆治疗公司 | 嵌合受体及其在免疫治疗中的应用 |
GB201417042D0 (en) * | 2014-09-29 | 2014-11-12 | Fkd Therapies Oy | Method |
JP6401871B2 (ja) | 2014-11-05 | 2018-10-10 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | パーキンソン病の治療のためのaadcポリヌクレオチド |
SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
EP3218484A4 (en) | 2014-11-14 | 2018-05-30 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
CN107428799A (zh) | 2015-01-13 | 2017-12-01 | 阿尔法韦士曼公司 | 纯化腺相关病毒(AAV)及/或重组腺相关病毒(rAAV)之方法及其梯度和流通式缓冲液 |
EP3054007A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
AU2016249798B2 (en) | 2015-04-14 | 2022-05-26 | Janssen Vaccines And Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
PL3319633T3 (pl) | 2015-07-07 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Szczepionka przeciwko rsv |
EP3319634B1 (en) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
US9663766B2 (en) | 2015-07-24 | 2017-05-30 | Bio-Rad Laboratories, Inc. | Methods for purifying adenovirus vectors |
EP3362472B1 (en) | 2015-10-16 | 2023-08-30 | The Trustees of Columbia University in the City of New York | Compositions and methods for inhibition of lineage specific antigens |
US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
SI3439672T1 (sl) | 2016-04-05 | 2021-02-26 | Janssen Vaccines & Prevention B.V. | Stabiliziran topen pre-fuzijski F protein RSV za uporabo v profilaksi okužbe z RSV |
JP7233928B2 (ja) | 2016-04-05 | 2023-03-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Rsvに対するワクチン |
US11261416B2 (en) * | 2016-04-14 | 2022-03-01 | Trizell Ltd. | Fixed-bed bioreactor with constant-flow pump / tubing system |
EP3604547A1 (en) * | 2016-04-14 | 2020-02-05 | Trizell Ltd. | Fixed-bed bioreactor with constant-flow pump/tubing system |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
EP3458588A4 (en) | 2016-05-18 | 2020-01-15 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
WO2017201258A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | CELL EXPANSION |
EA039124B1 (ru) | 2016-05-30 | 2021-12-08 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизированные f-белки rsv до слияния |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
EP3472327B1 (en) | 2016-06-20 | 2020-08-19 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
EP3484506A1 (en) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
EP3831281A1 (en) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018080573A1 (en) | 2016-10-28 | 2018-05-03 | Massachusetts Institute Of Technology | Crispr/cas global regulator screening platform |
US10294452B2 (en) | 2016-11-22 | 2019-05-21 | Dao-Yao He | Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells |
WO2018106888A1 (en) * | 2016-12-08 | 2018-06-14 | Temple University-Of The Commonwealth System Of Higher Education | Small animal models for in vivo testing of polyomavirus therapeutics |
WO2018148246A1 (en) | 2017-02-07 | 2018-08-16 | Massachusetts Institute Of Technology | Methods and compositions for rna-guided genetic circuits |
JP7393945B2 (ja) | 2017-03-31 | 2023-12-07 | テルモ ビーシーティー、インコーポレーテッド | 細胞増殖 |
WO2018204803A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)治療組成物および方法 |
CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
EP3808849A1 (en) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
CN107384873A (zh) * | 2017-09-05 | 2017-11-24 | 成都汇宇生物技术有限公司 | 重组腺病毒的纯化方法 |
AU2018333566A1 (en) | 2017-09-15 | 2020-02-27 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
EP3707250A1 (en) * | 2017-11-08 | 2020-09-16 | Blue Sky Vaccines GmbH | So3 chromatography for use in a method for virus purification |
US20210010028A1 (en) | 2018-03-06 | 2021-01-14 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
JP2021521852A (ja) | 2018-04-27 | 2021-08-30 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | Aadcウイルスベクターの効力を測定する方法 |
CA3099306A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
TW202015742A (zh) | 2018-05-15 | 2020-05-01 | 美商航海家醫療公司 | 投遞腺相關病毒(aav)之組成物和方法 |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
EP3793615A2 (en) | 2018-05-16 | 2021-03-24 | Voyager Therapeutics, Inc. | Directed evolution of aav to improve tropism for cns |
JP2021529513A (ja) | 2018-07-02 | 2021-11-04 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症および脊髄に関連する障害の治療 |
EP3826719A1 (en) | 2018-07-24 | 2021-06-02 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
JP2022520138A (ja) | 2018-08-28 | 2022-03-29 | ブイオーアール バイオファーマ インコーポレーテッド | 遺伝子操作された造血幹細胞およびそれらの使用 |
WO2020072683A1 (en) | 2018-10-02 | 2020-04-09 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
TW202035689A (zh) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | 測量病毒載體粒子的效價及強度之方法 |
WO2020077165A1 (en) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2020123524A1 (en) * | 2018-12-11 | 2020-06-18 | Erbi Biosystems, Inc. | Methods of manufacturing cell based products using small volume perfusion processes |
US20220064671A1 (en) | 2019-01-18 | 2022-03-03 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
WO2020172509A1 (en) | 2019-02-21 | 2020-08-27 | Unleash Immuno Oncolytics, Inc. | Oncolytic adenoviral vector and methods of use |
CN110093455B (zh) * | 2019-04-27 | 2020-03-17 | 中国医学科学院病原生物学研究所 | 一种呼吸道病毒的检测方法 |
WO2020223274A1 (en) | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
CN112175996A (zh) * | 2019-07-05 | 2021-01-05 | 杭州荣泽生物科技有限公司 | 一种基因治疗载体的制备方法和用途 |
EP4010465A1 (en) | 2019-08-09 | 2022-06-15 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
WO2021041485A1 (en) | 2019-08-26 | 2021-03-04 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
US20220333133A1 (en) | 2019-09-03 | 2022-10-20 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
US20220389361A1 (en) * | 2019-11-15 | 2022-12-08 | City Of Hope | System, device and method for production of bioproduct including high density cell respirator for intensified production of adeno-associated viruses |
CN110894494B (zh) * | 2019-11-22 | 2022-09-27 | 广西梧州制药(集团)股份有限公司 | 一种大规模高密度悬浮培养293细胞高产腺病毒的方法 |
US20230131352A1 (en) | 2020-04-01 | 2023-04-27 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
BR112022020753A2 (pt) | 2020-04-15 | 2022-12-20 | Voyager Therapeutics Inc | Compostos de ligação a tau |
GB202005732D0 (en) | 2020-04-20 | 2020-06-03 | Synpromics Ltd | Regulatory nucleic acid sequences |
CA3182970A1 (en) | 2020-05-13 | 2021-11-18 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
EP4192514A1 (en) | 2020-08-06 | 2023-06-14 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
CN112226418B (zh) * | 2020-09-25 | 2022-07-08 | 阜外华中心血管病医院 | 重组腺相关病毒纯化方法 |
IL301955A (en) | 2020-10-07 | 2023-06-01 | Asklepios Biopharmaceutical Inc | Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21 |
CN112293394B (zh) * | 2020-10-30 | 2022-11-25 | 海南德安欣有害生物防治科技有限公司 | 一种捕鼠装置及捕鼠方法 |
IL302128A (en) | 2020-11-02 | 2023-06-01 | Biomarin Pharm Inc | A process for the enrichment of adeno-associated virus |
GB202019454D0 (en) * | 2020-12-10 | 2021-01-27 | Chancellor Masters And Scholars Of The Univ Of Oxford | Method for purifying virus |
TW202246516A (zh) | 2021-03-03 | 2022-12-01 | 美商航海家醫療公司 | 病毒蛋白之控制表現 |
WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2023034980A1 (en) | 2021-09-03 | 2023-03-09 | Bomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034997A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034990A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034989A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034996A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034994A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
AU2022349103A1 (en) | 2021-09-27 | 2024-03-28 | Sotio Biotech Inc. | Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof |
CA3235632A1 (en) | 2021-11-02 | 2023-05-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023091909A1 (en) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
WO2023091948A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023111580A1 (en) | 2021-12-16 | 2023-06-22 | University Of Dundee | Targeted degradation of alpha-synuclein |
WO2023147374A2 (en) | 2022-01-25 | 2023-08-03 | Voyager Therapeutics, Inc. | Baculovirus expression system |
WO2023154693A1 (en) | 2022-02-08 | 2023-08-17 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
GB202201713D0 (en) | 2022-02-10 | 2022-03-30 | Univ Dundee | An affinity directed phosphatase system for targeted protein dephosphorylation |
CN115354033A (zh) * | 2022-03-25 | 2022-11-18 | 上海碧博生物医药科技有限公司 | 一种细胞裂解液、细胞裂解方法及该方法在收获aav的应用 |
WO2023235791A1 (en) | 2022-06-02 | 2023-12-07 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024006741A1 (en) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024040208A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024064863A2 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors |
WO2024064856A1 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of cardiomyopathy with aav gene therapy vectors |
CN117551624A (zh) * | 2024-01-11 | 2024-02-13 | 深圳源兴基因技术有限公司 | 一种基于无血清悬浮扩增的高效回收腺病毒的方法 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US789244A (en) * | 1902-10-01 | 1905-05-09 | Hans Thormeyer | Steam-turbine. |
US824544A (en) * | 1905-12-04 | 1906-06-26 | George Hossege | Pipe-hanger. |
US4222743A (en) | 1978-07-20 | 1980-09-16 | Wang Wei Kung | Method and apparatus for detecting biological particles by fluorescent stain |
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4539020A (en) | 1983-07-10 | 1985-09-03 | Kawasaki Steel Corporation | Methods for obtaining high-purity carbon monoxide |
JPS6147187A (ja) | 1984-08-10 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 狂犬病ウイルスの精製方法 |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5173418A (en) * | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5106841A (en) * | 1986-05-13 | 1992-04-21 | Chai-Tech Corporation | Antiviral compositions and method for their use |
EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
US5591624A (en) * | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
JPH0761955B2 (ja) | 1988-04-28 | 1995-07-05 | 国立予防衛生研究所長 | 凍結乾燥a型肝炎ワクチン |
US5219752A (en) * | 1988-05-25 | 1993-06-15 | Teijin, Limited | Process for continuously culturing adherent animal cells |
JPH04502995A (ja) | 1989-01-16 | 1992-05-28 | テレフンケン フェルンゼー ウント ルントフンク ゲゼルシャフト ミット ベシュレンクテル ハフツング | コンパチブルな周波数多重テレビジョン方式 |
US5221958A (en) * | 1989-05-01 | 1993-06-22 | Wolfram Bohnenkamp | Reflection fluorometer |
DE69023488T2 (de) | 1989-12-12 | 1996-05-09 | Lidak Pharmaceuticals | BESTIMMUNG FREIER FETTSäUREN. |
IT1238231B (it) | 1989-12-18 | 1993-07-12 | Consiglio Nazionale Ricerche | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori |
US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
NO312681B1 (no) | 1990-08-24 | 2002-06-17 | Univ California | Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet |
US6410010B1 (en) * | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
IT1248075B (it) | 1991-06-18 | 1995-01-05 | Sclavo Spa | Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono. |
EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
US5323008A (en) | 1992-03-23 | 1994-06-21 | Diatron Corporation | Fluorometer detection system |
EP0713397B1 (en) | 1992-03-24 | 2002-12-11 | United Cancer Research Institute | Vaccine containing live virus |
US5428011A (en) | 1992-06-16 | 1995-06-27 | Procyon Biopharma, Inc. | Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma |
US5733720A (en) * | 1992-06-18 | 1998-03-31 | Washington University | Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor |
WO1994002638A1 (en) | 1992-07-17 | 1994-02-03 | Aprogenex, Inc. | Free radical scavengers useful for reducing autofluorescence in fixed cells |
AU676204B2 (en) | 1992-09-18 | 1997-03-06 | Canji, Inc. | Gene therapy by retroviral vector with tumor suppressive gene |
US5733721A (en) | 1992-11-20 | 1998-03-31 | The Board Of Regents Of The University Of Oklahoma | Cell analysis method using quantitative fluorescence image analysis |
EP0682697A4 (en) | 1993-01-29 | 1997-07-30 | New Brunswick Scientific Co | METHOD AND APPARATUS FOR CULTURING ANCHOR AND SUSPENSION CELLS. |
US5604096A (en) | 1993-03-04 | 1997-02-18 | Schaeffer; Warren I. | Fluorometric quantitation of mycoplasmas |
US5994314A (en) | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
AU6945694A (en) | 1993-05-06 | 1994-12-12 | Dade International Inc. | Human papillomavirus detection assay |
US5421339A (en) | 1993-05-12 | 1995-06-06 | Board Of Regents, The University Of Texas System | Diagnosis of dysplasia using laser induced fluoroescence |
US6686200B1 (en) * | 1993-08-31 | 2004-02-03 | Uab Research Foundation | Methods and compositions for the large scale production of recombinant adeno-associated virus |
CA2158935A1 (en) | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
TW442569B (en) * | 1993-10-25 | 2001-06-23 | Canji Inc | Recombinant adenoviral vector |
EP0738319A4 (en) * | 1994-01-12 | 2000-03-29 | Genetic Therapy Inc | Purification of retroviral vectors |
HRP950097A2 (en) | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
US5498537A (en) * | 1994-03-09 | 1996-03-12 | Cellco, Inc. | Serum-free production of packaged viral vector |
JP3313117B2 (ja) | 1994-03-22 | 2002-08-12 | ザ イミューン リスポンス コーポレイション | ウイルス粒子の効率の高い生産および単離 |
US5521083A (en) * | 1994-05-13 | 1996-05-28 | The Research Foundation Of State University Of New York Et Al. | Large granular lymphocyte leukemia associated virus |
AU3551195A (en) * | 1994-09-23 | 1996-04-09 | Somatix Therapy Corporation | Chimeric adenovirus for gene delivery |
US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
US6348343B2 (en) * | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
US5837520A (en) * | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
US5744304A (en) * | 1995-05-30 | 1998-04-28 | Board Of Regents, The University Of Texas System | Inflammation-induced expression of a recombinant gene |
US5772888A (en) | 1995-07-27 | 1998-06-30 | Massachusetts Institute Of Technology | Separation and/or concentration of an analyte from a mixture using a two-phase aqueous micellar system |
CA2228128C (fr) * | 1995-08-01 | 2011-03-29 | Pasteur Merieux Serums & Vaccins | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu |
CA2625279A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
CZ296810B6 (cs) | 1995-11-30 | 2006-06-14 | Board Of Regents, The University Of Texas System | Léciva pro lécbu nádoru |
US5910434A (en) * | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
AR006240A1 (es) * | 1996-03-14 | 1999-08-11 | Fuller H B Licensing Financ | Adhesivo de fusion caliente que comprende interpolimeros, articulo no tejido que lo comprende, procedimiento de polimerizacion para preparlo y caja, envase, bandeja y libro unidos con dicho adhesivo |
JPH09262099A (ja) * | 1996-03-28 | 1997-10-07 | Aisin Seiki Co Ltd | フルオレセイン誘導体リン酸エステルによる核酸等の検出方法 |
AU3447097A (en) * | 1996-07-01 | 1998-01-21 | Rhone-Poulenc Rorer S.A. | Method for producing recombinant adenovirus |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
CN1244215B (zh) | 1996-11-20 | 2010-11-03 | 荷兰克鲁塞尔公司 | 改进的腺病毒载体生产和纯化方法 |
JP2001506126A (ja) | 1996-12-13 | 2001-05-15 | シェーリング コーポレイション | ウイルスの精製方法 |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
US6168944B1 (en) * | 1997-01-31 | 2001-01-02 | Schering Corporation | Methods for cultivating cells and propagating viruses |
BR9807418A (pt) | 1997-02-18 | 2002-01-22 | Canji Inc | Terapia de gene supressor de tumor combinado e quimioterapia no tratamento de neoplasmas |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
US6130313A (en) | 1997-10-02 | 2000-10-10 | Clontech Laboratories, Inc. | Rapidly degrading GFP-fusion proteins |
CN100374551C (zh) | 1998-02-17 | 2008-03-12 | 先灵公司 | 含有病毒的组合物以及浓缩病毒制剂的方法 |
US5922576A (en) | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
AU754999B2 (en) | 1998-03-10 | 2002-11-28 | Large Scale Proteomics Corporation | Detection and characterization of microorganisms |
US6265151B1 (en) | 1998-03-27 | 2001-07-24 | Seroptix, Inc. | Apparatus and method for infectious disease detection |
SK15682000A3 (sk) * | 1998-04-22 | 2001-05-10 | Genvec, Inc. | Účinné čistenie adenovírusu |
US6171790B1 (en) | 1998-05-01 | 2001-01-09 | Incyte Pharmaceuticals, Inc. | Human protease associated proteins |
AU4188599A (en) | 1998-05-15 | 1999-12-06 | Geron Corporation | Method and apparatus for detecting hazardous agents |
ATE268470T1 (de) * | 1998-06-30 | 2004-06-15 | Lamina Inc | Zytologische und histologische fixier- zusammensetzung und verfahren zur verwendung |
EP1102977A1 (en) | 1998-08-08 | 2001-05-30 | Imperial Cancer Research Technology Limited | Fluorescence assay for biological systems |
US5965358A (en) | 1998-08-26 | 1999-10-12 | Genvec, Inc. | Method for assessing the relative purity of viral gene transfer vector stocks |
US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
JP2003523169A (ja) | 1998-12-31 | 2003-08-05 | アバンテイス・フアルマ・エス・アー | ウイルス粒子の分離法 |
US6316185B1 (en) | 1999-09-29 | 2001-11-13 | Mountain View Pharmaceuticals, Inc. | Quantitation of viruses by light scattering |
JP2002054561A (ja) | 2000-08-08 | 2002-02-20 | Toyota Industries Corp | 容量可変型圧縮機の制御弁及び容量可変型圧縮機 |
US6447995B1 (en) * | 2000-10-04 | 2002-09-10 | Genvec, Inc. | Utilizing intrinsic fluorescence to detect adenovirus |
DE10050114A1 (de) | 2000-10-09 | 2002-04-25 | Wolf Gmbh Richard | Verwendung einer Gelmasse |
AU2003268210A1 (en) | 2002-08-28 | 2004-03-19 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
US20040229335A1 (en) | 2003-05-15 | 2004-11-18 | Introgen Therapeutics, Inc. | Methods and compositions for the production of adenoviral vectors |
-
1997
- 1997-11-20 CN CN971812543A patent/CN1244215B/zh not_active Expired - Lifetime
- 1997-11-20 AT AT97950677T patent/ATE348155T1/de active
- 1997-11-20 CA CA2272820A patent/CA2272820C/en not_active Expired - Lifetime
- 1997-11-20 BR BR9713368-0A patent/BR9713368A/pt not_active Application Discontinuation
- 1997-11-20 EP EP06012869A patent/EP1707631A3/en not_active Withdrawn
- 1997-11-20 ES ES97950677T patent/ES2278399T3/es not_active Expired - Lifetime
- 1997-11-20 EP EP06025694A patent/EP1760151B1/en not_active Expired - Lifetime
- 1997-11-20 US US08/975,519 patent/US6194191B1/en not_active Expired - Lifetime
- 1997-11-20 WO PCT/US1997/021504 patent/WO1998022588A2/en active IP Right Grant
- 1997-11-20 EP EP97950677A patent/EP0968284B1/en not_active Expired - Lifetime
- 1997-11-20 DE DE69737107T patent/DE69737107T2/de not_active Expired - Lifetime
- 1997-11-20 JP JP52396598A patent/JP4492826B2/ja not_active Expired - Lifetime
- 1997-11-20 KR KR10-1999-7004446A patent/KR100503701B1/ko not_active IP Right Cessation
- 1997-11-20 AU AU53617/98A patent/AU732703B2/en not_active Expired
- 1997-11-20 ES ES06025694T patent/ES2383640T3/es not_active Expired - Lifetime
- 1997-11-20 NZ NZ335947A patent/NZ335947A/xx not_active IP Right Cessation
- 1997-11-20 AT AT06025694T patent/ATE550429T1/de active
-
1999
- 1999-05-19 NO NO992389A patent/NO992389L/no not_active Application Discontinuation
-
2000
- 2000-04-24 US US09/556,570 patent/US6726907B1/en not_active Expired - Lifetime
-
2001
- 2001-12-27 US US10/033,571 patent/US7510875B2/en not_active Expired - Fee Related
- 2001-12-27 US US10/033,491 patent/US20030008375A1/en not_active Abandoned
-
2004
- 2004-07-30 US US10/909,066 patent/US7445930B2/en not_active Expired - Fee Related
-
2006
- 2006-08-23 US US11/508,780 patent/US20070155008A1/en not_active Abandoned
-
2007
- 2007-07-19 HK HK07107808.0A patent/HK1107116A1/xx not_active IP Right Cessation
-
2009
- 2009-10-02 US US12/572,943 patent/US20100055763A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
Harunal et al.SEPARATION OF ADENOVIRUS BY CHROMATOGRAPHYON DEAE-CELLULOSE.VIROLOGY13.1961,264-267. |
Harunal et al.SEPARATION OF ADENOVIRUS BY CHROMATOGRAPHYON DEAE-CELLULOSE.VIROLOGY13.1961,264-267. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108085301A (zh) * | 2016-11-22 | 2018-05-29 | 贺道耀 | 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒 |
CN108085301B (zh) * | 2016-11-22 | 2021-10-26 | 贺道耀 | 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1244215B (zh) | 改进的腺病毒载体生产和纯化方法 | |
CA2353787C (en) | An improved method for the production and purification of adenoviral vectors | |
US20060166364A1 (en) | Use of flexible bag containers for viral production | |
WO1998022588A9 (en) | An improved method for the production and purification of adenoviral vectors | |
US20040106184A1 (en) | Chromatographic methods for adenovirus purification | |
WO1998021350A1 (en) | Diminishing viral gene expression by promoter replacement | |
JP2007500015A (ja) | アデノウイルスベクター産生のための方法および組成物 | |
JP2008518632A (ja) | アデノウイルスベクターの製造および精製のための新規方法 | |
WO1999027123A9 (en) | Modified sv40 viral vectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: NETHERLANDS CLUZET CO., LTD. Free format text: FORMER OWNER: INTROGEN THERAPEUTIC INC Effective date: 20100603 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: TEXAS STATE, USA TO: LEIDEN, NETHERLANDS |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100603 Address after: Leiden Applicant after: Holland Crusell B.V. Address before: texas Applicant before: Introgen Therapeutic Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CI01 | Publication of corrected invention patent application |
Correction item: Inventor Correct: Zhang Shuyuan|The C. twin|Wu Zheng|Zhuo Tuyong False: Zhang Shuyuan|Wu Zheng|Zhuo Tuyong Number: 44 Volume: 26 |
|
CI03 | Correction of invention patent |
Correction item: Inventor Correct: Zhang Shuyuan|The C. twin|Wu Zheng|Zhuo Tuyong False: Zhang Shuyuan|Wu Zheng|Zhuo Tuyong Number: 44 Page: The title page Volume: 26 |
|
ERR | Gazette correction |
Free format text: CORRECT: INVENTOR; FROM: ZHANG SHUYUAN; WU ZHENG, ZHUO TUYONG TO: ZHANG SHUYUAN; THWIN CAPUCINE, WUZHENG, ZHUO TUYONG |
|
CX01 | Expiry of patent term |
Granted publication date: 20101103 |